Quality control of hemoglobin-based blood substitutes

Area of Science:

• Biomedical Engineering
• Hematology
• Biochemistry

Background:

• Hemoglobin-based blood substitutes (HBBS) aim to replicate blood's volume expansion and oxygen delivery functions.
• Current HBBS development faces challenges due to inadequate characterization and quality control of starting materials like stroma-free hemoglobin (SFH).
• This can lead to product artifacts, hindering therapeutic advancement.

Purpose of the Study:

• To advocate for standardized, high-quality starting materials for HBBS preparation.
• To emphasize the necessity of thorough characterization and quality control in HBBS development.
• To address safety and toxicity concerns for commercial-scale HBBS production.

Main Methods:

• Review of existing methodologies in HBBS preparation.
• Analysis of the impact of starting material quality on final product integrity.
• Case for using affinity-purified hemoglobin and modified hemoglobin derivatives.

Main Results:

• Inadequate characterization of hemoglobin (Hb) and its derivatives (e.g., PLP-Hb, ATP-Hb) can introduce artifacts.
• Affinity-purified hemoglobin and modified hemoglobins are proposed as superior starting materials.
• Rigorous quality control is essential to resolve safety and toxicity issues.

Conclusions:

• Standardizing starting materials like affinity-purified hemoglobin is key to reliable HBBS development.
• Thorough quality control and characterization are non-negotiable for ensuring HBBS safety and efficacy.
• Addressing these issues is critical for the successful commercialization of HBBS.